ENZN - Enzon Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Enzon Pharmaceuticals, Inc.

20 Commerce Drive
Suite 135
Cranford, NJ 07016
United States
732-980-4500
http://www.enzon.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew RackearCEO & Sec.190.04kN/A1954
Mr. Richard L. FeinsteinVP of Fin. & CFO172.52kN/A1943
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Corporate Governance

Enzon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.